# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $170 price...
Piper Sandler analyst Biren Amin initiates coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight rating and annou...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added ...
Sarepta Therapeutics will replace Shockwave Medical in the S&P MidCap 400 effective prior to the opening of trading on Mon...
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recen...
RBC Capital analyst Brian Abrahams downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Outperform to Sector Perform and lower...